Published in Immunol Today on March 01, 1995
Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol (2007) 1.15
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens (2008) 1.13
Soluble HLA revisited. Leuk Res (2006) 0.93
Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia. Ann Rheum Dis (2000) 0.86
Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest (1997) 0.86
Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies. Clin Exp Immunol (2015) 0.83
A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth. PLoS One (2011) 0.83
Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis (1997) 0.81
Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy. Immunology (2002) 0.77
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. J Clin Immunol (2000) 0.77
Modifications of general parameters of immune activation in the sera of Sicilian patients with Boutonneuse fever. Clin Exp Immunol (1998) 0.76
Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno-peptidomes required for biomarker discovery. Proteomics (2016) 0.75
Serum HLA class I: clinical significance in organ transplantation. Immunol Today (1996) 0.75
Decreased levels of serum soluble HLA class I antigens in HLA-B27 positive spondyloarthropathies. Ann Rheum Dis (2006) 0.75
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med (2015) 0.75
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. J Immunol Methods (1976) 2.30
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66
Structural polymorphism of human DR antigens. Nature (1979) 1.63
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med (1979) 1.63
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Autoimmune hemolytic anemia and human immunodeficiency virus (HIV) infection. Ann Intern Med (1988) 1.54
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood (1999) 1.48
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens (2005) 1.45
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. Clin Exp Rheumatol (1997) 1.43
TAP off--tumors on. Immunol Today (1997) 1.43
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol (1980) 1.38
Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol (2001) 1.36
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens (2003) 1.36
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
MHC antigens in human melanomas. Semin Cancer Biol (1991) 1.28
Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today (1999) 1.26
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A (1992) 1.24
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res (1994) 1.24
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res (1998) 1.21
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol (1981) 1.21
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest (1991) 1.21
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol (1987) 1.18
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res (1988) 1.17
Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol (1989) 1.17
Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. Immunogenetics (1981) 1.16
CSPG4 in cancer: multiple roles. Curr Mol Med (2010) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics (1983) 1.15
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens (2008) 1.13
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens (1999) 1.11
Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol (1992) 1.10
Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol (1986) 1.10
Cell cycle and the differential expression of HLA-A,B and HLA-DR antigens on human B lymphoid cells. Proc Natl Acad Sci U S A (1980) 1.09
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother (2005) 1.07
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer (1999) 1.07
A simple microabsorption technique for HL-A typing. Proc Soc Exp Biol Med (1972) 1.07
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol (1989) 1.06
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res (1993) 1.05
Biologic and chemical characterization of HLA antigens in human serum. J Immunol (1977) 1.05
Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res (1993) 1.04
IL-15/IL-15Ralpha intracellular trafficking in human melanoma cells and signal transduction through the IL-15Ralpha. Oncogene (2000) 1.03
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol (2007) 1.03
Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation (1982) 1.03
Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res (1981) 1.02
HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer (1987) 1.02
Immune cell circulating subsets are affected by gonadal function. Life Sci (1994) 1.02
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst (1981) 1.02
Signal transduction in lymphocyte activation through crosslinking of HLA class I molecules. Hum Immunol (1989) 1.02
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst (1982) 1.02
The free and the beta 2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28. Immunogenetics (1981) 1.00
Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res (1984) 0.99
Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol (1993) 0.99
Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med (1989) 0.99
Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. J Immunol Methods (1990) 0.98
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol (2000) 0.98
Ia-like antigens on human T lymphocytes: relationship to other surface markers, role in mixed lymphocyte reactions, and structural profile. J Immunol (1980) 0.98
Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. Proc Natl Acad Sci U S A (1973) 0.98
Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods (1993) 0.97
Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst (1984) 0.97
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol (1983) 0.97